While OA knee pain presents the largest opportunity for ZILRETTA, we believe the product holds great potential in other indications, including hip and shoulder OA pain and adhesive capsulitis also known as frozen shoulder. As we previously reported, in December, we enrolled a first patient in a double-blind, placebo-controlled Phase 3b trial to evaluate the safety and efficacy of ZILRETTA in patients with hip OA.